J&J's Invokana SNDA Gets Priority Review Status From FDA
Zacks Investment Research | May 23, 2019 08:20AM ET
Johnson & Johnson (NYSE:JNJ) announced that the FDA has granted priority review to a supplemental new drug application (sNDA) looking for label expansion of its type II diabetes medicine, Invokana. The sNDA is looking for approval of Invokana, a SGLT2 inhibitor, for slowing the progression of chronic kidney disease (CKD) in patients with type II diabetes when used in addition to standard of care.
The sNDA filing is based on data from the phase III CREDENCE renal outcomes study, data from which has shown that Invokana significantly reduces the risk of renal failure, dialysis or kidney transplantation, and renal or cardiovascular death in patients with type II diabetes and CKD.J&J had filed a sNDA in March to include data from the CREDENCE study on the label of Invokana.
We remind investors that in July last year, the study was stopped early based on positive pre-specified efficacy data. The decision was based on a recommendation from the study’s Independent Data Monitoring Committee (IDMC) that met to review the data during a planned interim analysis.
Almost half of all patients with type II diabetes develop CKD, causing a high risk of kidney failure and cardiovascular disease. If the sNDA is approved, Invokana will be the first new therapy in nearly 20 years to reduce the risk of kidney failure and prevent life-threatening cardiovascular events in patients with CKD and type II diabetes when added to current standard of care
In October last year, the U.S. label of Invokana was updated to include the cardiovascular outcomes data from the CANVAS program. With the label expansion, Invokana can now be prescribed to reduce the risk of cardiovascular events like heart attack, stroke or cardiovascular death in adults with type II diabetes and established cardiovascular disease. However, the label includes a warning about an increased risk of amputations.
Notably, many pharma companies are working hard to get the labels of their diabetes medicines updated to include renal outcomes data. A phase III study is evaluating Lilly’s (NYSE:LLY) successful SGLT2 inhibitor, Jardiance in CKD.
J&J’s shares have risen 7.5% this year so far against the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.